Page last updated: 2024-11-05

4-dimethylaminopyridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-Dimethylaminopyridine (DMAP) is a highly effective catalyst in organic synthesis. It is a nucleophilic base, commonly used as a catalyst for acylation reactions, particularly in the formation of esters and amides. The synthesis of DMAP typically involves the reaction of 4-chloropyridine with dimethylamine. DMAP is a highly efficient catalyst because it can activate the carbonyl group of acyl chlorides, making them more susceptible to nucleophilic attack. It is widely studied due to its ability to accelerate a wide range of reactions, including those involving acylations, alkylations, and condensations. DMAP's importance lies in its ability to improve the efficiency and selectivity of organic reactions, making it a valuable tool for organic chemists.'

4-dimethylaminopyridine: catalyst for acetylation of hydroxy cpds; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID14284
CHEMBL ID3561645
CHEBI ID182593
SCHEMBL ID189
MeSH IDM0044996

Synonyms (163)

Synonym
AC-13385
5-22-09-00112 (beilstein handbook reference)
pfp1r6p0s8 ,
unii-pfp1r6p0s8
CHEBI:182593
4-dimethylaminopyridine
dmap
4-dmap
gamma-(dimethylamino)pyridine
einecs 214-353-5
4-(dimethylamino)pyridine
ccris 6176
n,n-dimethyl-4-pyridinamine
brn 0110354
p-dimethylaminopyridine
pyridine, 4-(dimethylamino)-
4-dimethylamino pyridine
1122-58-3
inchi=1/c7h10n2/c1-9(2)7-3-5-8-6-4-7/h3-6h,1-2h
n,n-dimethylpyridin-4-amine
4-pyridinamine, n,n-dimethyl-
AR-360/40355729
n,n-dimethyl-n-(4-pyridinyl)amine
4-(dimethylamino)pyridine, prilled, 99%
4-(dimethylamino)pyridine, reagentplus(r), >=99%
STK865133
n-(4-pyridyl)dimethylamine
D1450
AKOS000120170
dimethyl-pyridin-4-yl-amine
4-(dimethylamino)-pyridine
4-dimethylaminopyridin
4-dimethylaminopyridine (dmap)
cas-1122-58-3
dtxsid0044369 ,
dtxcid8024369
tox21_302184
NCGC00257546-01
4-(n,n-dimethylamino)pyridine
4-dimethylamino-pyridine
n,n-dimethyl-4-aminopyridine
887925-31-7
dimethyl-4-pyridylamine
FT-0602715
AM20050674
CX1367
valaciclovir hydrochloride hydrate impurity g [ep impurity]
valaciclovir hydrochloride impurity g [ep impurity]
dmap [mi]
BP-21319
SCHEMBL189
PS-4600
p-n,n-dimethylaminopyridine
4(dimethylamino) pyridine
4--(n,n'-dimethylamino) pyridine
4-(dimethylamino)pryidine
4-(n, n-dimethylamino)-pyridine
4-(n,n-dimethyl)aminopyridine
p-(dimethylamino)-pyridine
4(n,n dimethylamino)pyridine
4-(n,n'-dimethylamino) pyridine
4-(dimethyl-amino)pyridine
4dimethylaminopyridine
4-dimethylaminopryidine
4-dimethylamino- pyridine
p-dimethylamino-pyridine
n, n-dimethyl-4-aminopyridine
4-(n,n-dimethyl-amino)pyridine
dimethyl-pyridin-4yl-amine
para-n,n-dimethylamino-pyridine
para-dimethylaminopyridine
4-dimethlaminopyridine
n,n dimethyl-4-pyridinamine
4-dimethlyaminopyridine
4-(n,n-dimethyiamino)pyridine
4- (dimethylamino)pyridine
n,n-dimethyl-pyridin-4-amine
4-dimethylaminopyridine-
4-dimetylamino- pyridine
4-(n, n-dimethylamino) pyridine
4-(n,n-dimethylamino) pyridine
4-[dimethylamino]pyridine
4-(n, n-dimethylamino)pyridine
4-(dimethyamino)pyridine
4-(n,n-dimethyamino)pyridine
4-(n,n dimethylamino)-pyridine
4-dimethyaminopyridine
4-(n,n'-dimethylamino)pyridine
4-(dimethylarnino)pyridine
4-dimethylaminopiridine
4-dimethylammopyridine
4-(n,n-dimethyl amino)pyridine
dimethylpyridin-4-yl-amine
4-dimetylaminopyridine
4(dimethylamino)pyridine
4-(n,n-dimethylamino)-pyridine
p-dimethylamino pyridine
4-dimethylarninopyridine
4(n,n-dimethylamino)pyridine
4-(dimethylamino)- pyridine
n,n-dimethylpyridin-4-amin
4-dimethylaminepyridine
4-dimethylamine pyridine
4-dimethylaminopyridme
4-dimethylaminopridine
n,n-dimethyl-4-pyridineamine
4-(dimethyl)aminopyridine
4-(dimethyl amino) pyridine
4-di-methylamino-pyridine
n,n-dimethyl 4-pyridinamine
4-di-methylaminopyridine
n,n-dimethyl-4-amino pyridine
4-(dimethyl-amino)-pyridine
4-(n,n,-dimethylamino)pyridine
n,n-dimethy-4-aminopyridine
n,n-dimethylpyridin -4-amine
4-dimethylamino pyridin
4-(dimethyl amino)pyridine
n,n-dimethylpyridine-4-amine
4-(n,n-dimetylamino)pyridine
4-(dimethlyamino)-pyridine
4-di methylaminopyridine
4- dimethylaminopyridine
4-dimetylamino-pyridine
4 -dimethylaminopyridine
para-(n,n-dimethylamino) pyridine
4-(dimethylamino-)pyridine
dimethylpyridin-4-ylamine
4-(dimethyiamino)pyridine
4-(dimethylamino) pyridine
4-dimethy-laminopyridine
n,n-dimethyl-pyridin-4-yl-amine
Q-200466
STR00352
.gamma.-(dimethylamino)pyridine
CHEMBL3561645 ,
mfcd00006418
CS-W008903
4-(dimethylamino)pyridine, pharmaceutical impurity standard
4-(dimethylamino)pyridine, chemdose(tm) tablets, loading: 0.04 mmol tablet.
F0001-0270
4-(dimethylamino)pyridine, puriss., >=99.0% (nt)
4-(dimethylamino)pyridine, purum, >=98.0% (nt)
valaciclovir impurity g, european pharmacopoeia (ep) reference standard
4-(dimethylamino)pyridine; >99%
FT-0725083
(4-dmap);4-dimethylaminopyridine
Q229897
BCP26534
dmap pound>>n,n-dimethylpyridin-4-amine
JGD ,
4-(dimethylamino)pyridine (dmap)
4-dimethylaminopyr
4-(n
n,n'-dimethyl-4-pyridinamine
SB40777
EN300-20577
bdbm50556493
valaciclovir impurity g
PD074147
4-dimethykaminopyridine (dmap)
HY-Y1089
Z104478964
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
dialkylarylamine
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency43.641219.739145.978464.9432AID1159509
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
lipid metabolic processCholine kinase alphaHomo sapiens (human)
phosphatidylethanolamine biosynthetic processCholine kinase alphaHomo sapiens (human)
phosphatidylcholine biosynthetic processCholine kinase alphaHomo sapiens (human)
lipid transportCholine kinase alphaHomo sapiens (human)
CDP-choline pathwayCholine kinase alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
choline kinase activityCholine kinase alphaHomo sapiens (human)
cholinesterase activityCholine kinase alphaHomo sapiens (human)
ethanolamine kinase activityCholine kinase alphaHomo sapiens (human)
protein tyrosine kinase activityCholine kinase alphaHomo sapiens (human)
ATP bindingCholine kinase alphaHomo sapiens (human)
protein homodimerization activityCholine kinase alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
cytosolCholine kinase alphaHomo sapiens (human)
lipid dropletCholine kinase alphaHomo sapiens (human)
cytosolCholine kinase alphaHomo sapiens (human)
cytoplasmCholine kinase alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1706113Binding affinity to human CKalpha1 assessed as dissociation constant by spectroflurometry2020European journal of medicinal chemistry, Dec-01, Volume: 207Synthesis, biological evaluation, in silico modeling and crystallization of novel small monocationic molecules with potent antiproliferative activity by dual mechanism.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (127)

TimeframeStudies, This Drug (%)All Drugs %
pre-199015 (11.81)18.7374
1990's11 (8.66)18.2507
2000's42 (33.07)29.6817
2010's54 (42.52)24.3611
2020's5 (3.94)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 59.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index59.18 (24.57)
Research Supply Index4.88 (2.92)
Research Growth Index4.88 (4.65)
Search Engine Demand Index95.92 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (59.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.76%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other130 (99.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]